On December 03, 2019, CymaBay Therapeutics, Inc. (NASDAQ:CBAY) shares gained 2.47% or 0.04 points to close at $1.66 with a heavy trading volume of 3.581 million shares. It opened the trading session at $1.6, the shares rose to $1.7 and dropped to $1.51, the range by which the price of stock traded the whole day. The company now has a market cap of $113 million and currently has 67.9 million outstanding shares. CymaBay Therapeutics, Inc. (CBAY) stock has plunged -66.53 percent of market value in 21 trading days.
CBAY stock’s trailing 3-year beta is 0.99, meaning there will be a lower rate of return, although posing a lower risk. The part of a firm’s profit given to each outstanding share of regular stock was -$1.43 share in the trailing 52 weeks. The stock’s value fallen -78.91 percent year to date (YTD) compared to a decline of -81.41 percent in 52 week’s period. The firm’s shares are still trading -88.14 percent below its 1-year high of $14.00 and 28.68 percent up from 52-week low of $1.29. The average consensus ranking on the company is 2.8, on a ranging where 5 is equal to a consensus sell rating. In other words, the mean analyst recommendations are ranking this stock as a sell.
CymaBay Therapeutics, Inc. (CBAY) is most likely going to rise 39.16 percent in the coming 12 months, as per price target approximations compiled by finviz. Nevertheless, they have set the price target at a $4-month high price target. This represents a whopping 140.96 percent increase from the current trading of shares. The 52-week median price target given by the analysts is $2, which means a return possibility of 20.48 percent in comparison with the closing price of the stock of $1.66 on December 03. The lowest price set for the stock is $2 — just above 20.48 percent from CBAY share price now.
Past records have indicated that shares in CymaBay Therapeutics, Inc. rose on 12 different earnings reaction days and we have yet to see whether this trend will play out and remain in place when the company reports upcoming earnings.
Let’s take a glimpse at some insider activity at CymaBay Therapeutics, Inc. (NASDAQ:CBAY) and observe the pattern. The earliest insider trade happened on 10/10/2019. Shah Sujal gathered a total of 5 thousand shares of the firm at average share price of $4.3. The total amount for the purchase was set at $21.5 thousand. On completing this exchange, the CEO account balance was 120 thousand shares. The stock lost -62.33 percent from that insider purchase. On 09/23/2019, Shah Sujal, CEO, did a purchase of 5 thousand shares at a price of $5.53 per share. This increased 27.65 thousand shares to the insider’s fortune and the stock experienced a -70.71 percent retreat in price since the news became public. This exchange saw 115 thousand shares get into the CEO account.
On 02/07/2019, Director GOLDFISCHER CARL recorded a sale transaction valued at $105.31 thousand. The sale at $9.02 a share has eliminated 11.68 thousand shares from the insider’s portfolio position. Meanwhile, shares price witnessed -82.04 percent decrease since the transaction reporting date. The company insider is left with 0 thousand shares remaining in the account. Shah Sujal, who works as CEO at the company, performed a purchase of 10 thousand shares in a transaction worth $65.4 thousand. The acquisition recorded on 12/21/2018 was priced at $6.54 per share. The stock price plunged -75.23 percent since the transaction. Shah Sujal currently holds a stake of 110 thousand in CBAY stock which is worth $182.6 thousand after the insider buying.
The stock is lingering around the initial support level of $1.55. After this, the following support is at the zone of $1.43. Up until the time the CBAY stock hit levels beyond the current one, bulls should have no alarm. In terms of its momentum, the stock’s RSI hit 24.73 on the daily chart, and this may be a cause for comfort. In case the price goes below $1.43 level on closing basis, there may be more profit booking with the stock growing weaker. Still, getting to the $1.74 level may cause a pull-back move approaching $1.81 mark.